Mostrar el registro sencillo del ítem

Artículo

dc.creatorJiménez Ruiz, José Antonioes
dc.creatorLópez Ramírez, Ceciliaes
dc.creatorLópez-Campos Bodineau, José Luises
dc.date.accessioned2023-05-09T14:08:07Z
dc.date.available2023-05-09T14:08:07Z
dc.date.issued2022-11-29
dc.identifier.citationJiménez Ruiz, J.A., López Ramírez, C. y López-Campos Bodineau, J.L. (2022). Spike protein of SARS-CoV-2 Omicron variant An in-silico study evaluating spike interactions and immune evasion. Frontiers in Public Health, 10, 1052241. https://doi.org/10.3389/fpubh.2022.1052241.
dc.identifier.issn2296-2565es
dc.identifier.urihttps://hdl.handle.net/11441/145724
dc.description.abstractBackground: The fundamentals of the infectivity and immune evasion of the SARS-CoV-2 Omicron variant are not yet fully understood. Here, we carried out an in-silico study analyzing the spike protein, the protein electrostatic potential, and the potential immune evasion. Methods: The analysis was based on the structure of the spike protein from two SARS-CoV-2 variants, the original Wuhan and the Botswana (Omicron). The full-length genome sequences and protein sequences were obtained from databanks. The interaction of the spike proteins with the human Angiotensin Converting Enzyme 2 (ACE2) receptor was evaluated through the open-source software. The Immune Epitope Database was used to analyze the potential immune evasion of the viruses. Results: Our data show that the Omicron spike protein resulted in 37 amino acid changes. The physicochemical properties of the spike had changed, and the electrostatic potentials differed between both variants. This resulted in a decrease in protein interactions, which does not establish a greater interaction with the ACE2 receptor. These changes compromise key receptor-binding motif residues in the SARS-CoV-2 spike protein that interact with neutralizing antibodies and ACE2. Conclusions: These mutations appear to confer enhanced properties of infectivity. The Omicron variant appears to be more effective at evading immune responses.es
dc.formatapplication/pdfes
dc.format.extent10 p.es
dc.language.isoenges
dc.publisherFrontiers Mediaes
dc.relation.ispartofFrontiers in Public Health, 10, 1052241.
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectSARS-CoV-2es
dc.subjectCOVID-19es
dc.subjectimmune evasiones
dc.subjectin-silicoes
dc.subjectcoronaviruses
dc.titleSpike protein of SARS-CoV-2 Omicron variant An in-silico study evaluating spike interactions and immune evasiones
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.publisherversionhttps://www.frontiersin.org/articles/10.3389/fpubh.2022.1052241/fulles
dc.identifier.doi10.3389/fpubh.2022.1052241es
dc.journaltitleFrontiers in Public Healthes
dc.publication.volumen10es
dc.publication.initialPage1052241es
dc.contributor.funderCIBER-Consorcio Centro de Investigación Biomédica en Red- (CIBERES)es
dc.contributor.funderInstituto de Salud Carlos IIIes
dc.contributor.funderMinisterio de Ciencia e Innovación (MICIN). Españaes

FicherosTamañoFormatoVerDescripción
Spike protein of SARS-CoV-2 ...2.022MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Atribución 4.0 Internacional